Based on the identification of the anti-tumor monomer components Uralenol and Kaempferol through network pharmacology, which are implicated in the pathways of non-small cell lung cancer, hepatocellular carcinoma, breast cancer, and colorectal cancer, it is proposed that these two components may serve as potential active ingredients in the anti-tumor activity of FSH. This evidence concerns the gene BRD2 and non-small cell lung carcinoma.